Search Results - "Sawyer, Elinor"

Genomic Evolution of Breast Cancer Metastasis and Relapse by Yates, Lucy R., Knappskog, Stian, Wedge, David, Farmery, James H.R., Gonzalez, Santiago, Martincorena, Inigo, Alexandrov, Ludmil B., Van Loo, Peter, Haugland, Hans Kristian, Lilleng, Peer Kaare, Gundem, Gunes, Gerstung, Moritz, Pappaemmanuil, Elli, Gazinska, Patrycja, Bhosle, Shriram G., Jones, David, Raine, Keiran, Mudie, Laura, Latimer, Calli, Sawyer, Elinor, Desmedt, Christine, Sotiriou, Christos, Stratton, Michael R., Sieuwerts, Anieta M., Lynch, Andy G., Martens, John W., Richardson, Andrea L., Tutt, Andrew, Lønning, Per Eystein, Campbell, Peter J.

“…Patterns of genomic evolution between primary and metastatic breast cancer have not been studied in large numbers, despite patients with metastatic breast…”
Get full text

Intraoperative radiotherapy for early breast cancer — insufficient evidence to change practice by Sasieni, Peter D., Sawyer, Elinor J.

“…We argue that the evidence remains insufficient for use of intraoperative radiotherapy (IORT) in women with early stage breast cancer outside of a clinical…”
Get full text

Reply to ‘Intraoperative radiotherapy for breast cancer: powerful evidence to change practice’ by Sasieni, Peter D., Sawyer, Elinor J.

Get full text

Learning to distinguish progressive and non-progressive ductal carcinoma in situ by Casasent, Anna K., Almekinders, Mathilde M., Mulder, Charlotta, Bhattacharjee, Proteeti, Collyar, Deborah, Thompson, Alastair M., Jonkers, Jos, Lips, Esther H., van Rheenen, Jacco, Hwang, E. Shelley, Nik-Zainal, Serena, Navin, Nicholas E., Wesseling, Jelle

“…Ductal carcinoma in situ (DCIS) is a non-invasive breast neoplasia that accounts for 25% of all screen-detected breast cancers diagnosed annually. Neoplastic…”
Get full text

SOX11 promotes invasive growth and ductal carcinoma in situ progression by Oliemuller, Erik, Kogata, Naoko, Bland, Philip, Kriplani, Divya, Daley, Frances, Haider, Syed, Shah, Vandna, Sawyer, Elinor J, Howard, Beatrice A

“…Here, we show that SOX11, an embryonic mammary marker that is normally silent in postnatal breast cells, is expressed in many oestrogen receptor‐negative…”
Get full text

Frequency of Pathogenic Germline Variants in CDH1, BRCA2, CHEK2, PALB2, BRCA1 , and TP53 in Sporadic Lobular Breast Cancer by Petridis, Christos, Arora, Iteeka, Shah, Vandna, Moss, Charlotte L, Mera, Anca, Clifford, Angela, Gillett, Cheryl, Pinder, Sarah E, Tomlinson, Ian, Roylance, Rebecca, Simpson, Michael A, Sawyer, Elinor J

“…Invasive lobular breast cancer (ILC) accounts for approximately 15% of invasive breast carcinomas and is commonly associated with lobular carcinoma (LCIS)…”
Get full text

Mutation detection in saliva from oral cancer patients by Ahmed, Ahmed A., Sborchia, Mateja, Bye, Hannah, Roman-Escorza, Maria, Amar, Ariella, Henley-Smith, Rhonda, Odell, Edward, McGurk, Mark, Simpson, Michael, Ng, Tony, Sawyer, Elinor J., Mathew, Christopher G.

“…•Frequently mutated genes in OSCC: TP53 (64%), FAT1 (27%), CDKN2A, CASP8 and DNAH7.•Tumor somatic mutations of OSCC can be detected in saliva DNA at high…”
Get full text

Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial by Coles, Charlotte E, Haviland, Joanne S, Kirby, Anna M, Griffin, Clare L, Sydenham, Mark A, Titley, Jenny C, Bhattacharya, Indrani, Brunt, A Murray, Chan, H Y Charlie, Donovan, Ellen M, Eaton, David J, Emson, Marie, Hopwood, Penny, Jefford, Monica L, Lightowlers, Sara V, Sawyer, Elinor J, Syndikus, Isabel, Tsang, Yat M, Twyman, Nicola I, Yarnold, John R, Bliss, Judith M

“…A tumour-bed boost delivered after whole-breast radiotherapy increases local cancer-control rates but requires more patient visits and can increase breast…”
Get full text

Epigenetic activation of SOX11 is associated with recurrence and progression of ductal carcinoma in situ to invasive breast cancer by Treekitkarnmongkol, Warapen, Shah, Vandna, Kai, Kazuharu, Katayama, Hiroshi, Wong, Justin, Ladha, Farah A., Nguyen, Tristian, Menegaz, Brian, Lu, Wei, Yang, Fei, Mino, Barbara, Tang, Ximing, Gagea, Mihai, Batra, Harsh, Raso, Maria Gabriela, Wistuba, Ignacio I., Krishnamurthy, Savitri, Pinder, Sarah E., Sawyer, Elinor J., Thompson, Alastair M., Sen, Subrata

“…Background Risk of recurrence and progression of ductal carcinoma in situ (DCIS) to invasive cancer remains uncertain, emphasizing the need for developing…”
Get full text

MED12, TERT promoter and RBM15 mutations in primary and recurrent phyllodes tumours by Garcia-Dios, Diego A, Levi, Dina, Shah, Vandna, Gillett, Cheryl, Simpson, Michael A, Hanby, Andrew, Tomlinson, Ian, Sawyer, Elinor J

“…Background: MED12 and TERT promoter mutations have been shown to be the most common somatic mutations in phyllodes tumours (PTs). The aims of this study were…”
Get full text

Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years by Petridis, Christos, Arora, Iteeka, Shah, Vandna, Megalios, Anargyros, Moss, Charlotte, Mera, Anca, Clifford, Angela, Gillett, Cheryl, Pinder, Sarah E, Tomlinson, Ian, Roylance, Rebecca, Simpson, Michael A, Sawyer, Elinor J

“…Ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive ductal breast cancer, and approximately 20% of screen-detected tumours are pure DCIS…”
Get full text

Risk factors for the development of invasive cancer in unresected ductal carcinoma in situ by Maxwell, Anthony J., Clements, Karen, Hilton, Bridget, Dodwell, David J., Evans, Andrew, Kearins, Olive, Pinder, Sarah E., Thomas, Jeremy, Wallis, Matthew G., Thompson, Alastair M., Thompson, Alastair, Clements, Karen, Dobson, Hilary, Dodwell, David, Evans, Andrew, Hanby, Andrew, Hilton, Bridget, Kearins, Olive, Lawrence, Gill, Maxwell, Anthony, Pinder, Sarah, Sawyer, Elinor, Sibbering, Mark, Speirs, Valerie, Thomas, Jeremy, Tomlinson, Ian, Ball, Graham, Wallis, Matthew, Wilcox, Maggie

“…The natural history of ductal carcinoma in situ (DCIS) remains uncertain. The risk factors for the development of invasive cancer in unresected DCIS are…”
Get full text

Mechanisms that clear mutations drive field cancerization in mammary tissue by Ciwinska, Marta, Messal, Hendrik A., Hristova, Hristina R., Lutz, Catrin, Bornes, Laura, Chalkiadakis, Theofilos, Harkes, Rolf, Langedijk, Nathalia S. M., Hutten, Stefan J., Menezes, Renée X., Jonkers, Jos, Prekovic, Stefan, Simons, Benjamin D., Scheele, Colinda L. G. J., van Rheenen, Jacco

“…Oncogenic mutations are abundant in the tissues of healthy individuals, but rarely form tumours 1 – 3 . Yet, the underlying protection mechanisms are largely…”
Get full text

Author Correction: Learning to distinguish progressive and non-progressive ductal carcinoma in situ by Casasent, Anna K., Almekinders, Mathilde M., Mulder, Charlotta, Bhattacharjee, Proteeti, Collyar, Deborah, Thompson, Alastair M., Jonkers, Jos, Lips, Esther H., van Rheenen, Jacco, Hwang, E. Shelley, Nik-Zainal, Serena, Navin, Nicholas E., Wesseling, Jelle

Get full text

One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT by Brunt, Adrian Murray, Haviland, Joanne S, Wheatley, Duncan A, Sydenham, Mark A, Bloomfield, David J, Chan, Charlie, Cleator, Suzy, Coles, Charlotte E, Donovan, Ellen, Fleming, Helen, Glynn, David, Goodman, Andrew, Griffin, Susan, Hopwood, Penelope, Kirby, Anna M, Kirwan, Cliona C, Nabi, Zohal, Patel, Jaymini, Sawyer, Elinor, Somaiah, Navita, Syndikus, Isabel, Venables, Karen, Yarnold, John R, Bliss, Judith M

“…FAST-Forward aimed to identify a 5-fraction schedule of adjuvant radiotherapy delivered in 1 week that was non-inferior in terms of local cancer control and as…”
Get full text

Unresected screen-detected ductal carcinoma in situ: Outcomes of 311 women in the Forget-Me-Not 2 study by Maxwell, Anthony J., Hilton, Bridget, Clements, Karen, Dodwell, David, Dulson-Cox, Joanne, Kearins, Olive, Kirwan, Cliona, Litherland, Janet, Mylvaganam, Senthurun, Provenzano, Elena, Pinder, Sarah E., Sawyer, Elinor, Shaaban, Abeer M., Sharma, Nisha, Stobart, Hilary, Wallis, Matthew G., Thompson, Alastair M.

“…The natural history of ductal carcinoma in situ (DCIS) is poorly understood. The aim of this cohort study was to determine the outcomes of women who had no…”
Get full text

Factors Affecting COVID-19 Outcomes in Cancer Patients: A First Report From Guy's Cancer Center in London by Russell, Beth, Moss, Charlotte, Papa, Sophie, Irshad, Sheeba, Ross, Paul, Spicer, James, Kordasti, Shahram, Crawley, Danielle, Wylie, Harriet, Cahill, Fidelma, Haire, Anna, Zaki, Kamarul, Rahman, Fareen, Sita-Lumsden, Ailsa, Josephs, Debra, Enting, Deborah, Lei, Mary, Ghosh, Sharmistha, Harrison, Claire, Swampillai, Angela, Sawyer, Elinor, D'Souza, Andrea, Gomberg, Simon, Fields, Paul, Wrench, David, Raj, Kavita, Gleeson, Mary, Bailey, Kate, Dillon, Richard, Streetly, Matthew, Rigg, Anne, Sullivan, Richard, Dolly, Saoirse, Van Hemelrijck, Mieke

“…There is insufficient evidence to support clinical decision-making for cancer patients diagnosed with COVID-19 due to the lack of large studies. We used data…”
Get full text

Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas by Palles, Claire, Cazier, Jean-Baptiste, Howarth, Kimberley M, Domingo, Enric, Jones, Angela M, Broderick, Peter, Kemp, Zoe, Spain, Sarah L, Guarino, Estrella, Salguero, Israel, Sherborne, Amy, Chubb, Daniel, Carvajal-Carmona, Luis G, Ma, Yusanne, Kaur, Kulvinder, Dobbins, Sara, Barclay, Ella, Gorman, Maggie, Martin, Lynn, Kovac, Michal B, Humphray, Sean, Lucassen, Anneke, Holmes, Christopher C, Bentley, David, Donnelly, Peter, Taylor, Jenny, Petridis, Christos, Roylance, Rebecca, Sawyer, Elinor J, Kerr, David J, Clark, Susan, Grimes, Jonathan, Kearsey, Stephen E, Thomas, Huw J W, McVean, Gilean, Houlston, Richard S, Tomlinson, Ian

“…Ian Tomlinson and colleagues report the identification of germline variants in POLE and POLD1 that are susceptibility alleles for colorectal cancer. POLE and…”
Get full text

Cohort profile of the Sloane Project: methodology for a prospective UK cohort study of >15 000 women with screen-detected non-invasive breast neoplasia by Clements, Karen, Dodwell, David, Hilton, Bridget, Stevens-Harris, Isabella, Pinder, Sarah, Wallis, Matthew G, Maxwell, Anthony J, Kearins, Olive, Sibbering, Mark, Shaaban, Abeer M, Kirwan, Cliona, Sharma, Nisha, Stobart, Hilary, Dulson-Cox, Joanne, Litherland, Janet, Mylvaganam, Senthurun, Provenzano, Elena, Sawyer, Elinor, Thompson, Alastair M

“…PurposeThe introduction of breast screening in the UK led to an increase in the detection of non-invasive breast neoplasia, predominantly ductal carcinoma in…”
Get full text

Serum Human Chorionic Gonadotropin (β- hCG) Clearance Curves in Women with Successfully Expectantly Managed Tubal Ectopic Pregnancies: A Retrospective Cohort Study by Helmy, Samir, Mavrelos, Dimitrios, Sawyer, Elinor, Ben-Nagi, Jara, Koch, Marianne, Day, Andrea, Jurkovic, Davor

“…To establish clearance curves for serum β -hCG in women with successfully expectantly managed tubal ectopic pregnancies. Retrospective cohort study. Non-…”
Get full text